Triple threat: new combo aims to tackle tough pancreatic cancer
NCT ID NCT07595172
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a mix of chemotherapy (NALIRIFOX), an immunotherapy drug (adebrelimab), and a special type of radiation (PULSAR) as a first treatment for people with advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this combination is safe and helps shrink tumors. About 55 adults aged 18-75 with good overall health and no prior treatment for their advanced cancer can join.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED AND METASTATIC PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
West China Hospital, Sichuan University
RECRUITINGChengdu, Sichuan, 610041, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Breath of life: new test could sniff out gut cancers before they spread
- Scientists hunt for biomarkers to catch pancreatic cancer before it strikes
- New PET tracer aims to spot hidden cancer spread in the abdomen
- Experimental drug inavolisib targets Hard-to-Treat pancreatic cancer
- Mini-Tumors in a dish may guide pancreatic cancer treatment
- New drug cocktail aims to tackle tough pancreatic cancer